# A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

> **NCT04520607** · PHASE3 · TERMINATED · sponsor: **Biosplice Therapeutics, Inc.** · enrollment: 276 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** Placebo
- **DRUG:** Lorecivivint

## Key facts

- **NCT ID:** NCT04520607
- **Lead sponsor:** Biosplice Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-25
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 276 (ACTUAL)
- **Why stopped:** Study OA-07 was designed to be conducted until the Sponsor closed it. Study OA-07 was administratively closed at Visit 6E (Week 100), with no safety concerns, one year into the open-label study as described in the protocol.
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520607, "A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04520607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*